新闻中心
关注我们
14 May
2019

MSCI香港微型指数纳入19只股份剔出8只股份

<AASTOCKS>

MSCI宣布2019年5月股票市场指数半年度检讨结果,其中香港微型指数纳入19个股份,同时剔出8只股份,所有变动将于5月28日收市后生效。

MSCI香港微型指数加入股份包括知临集团(APTORUM GROUP),亚证地产(00271.HK),奥星生命科技(06118.HK),优品360(02360.HK),人和科技(08140.HK) ,中国中石控股(01191.HK),中国通海金融(00952.HK),德基科技(01301.HK),广骏集团(08516.HK),长城环亚(00583.HK),兴铭控股( 08425.HK),港亚控股(01723.HK),香港金融集团(00007.HK),叙福楼集团(01978.HK),仁智国际(08082.HK),成志控股(01741.HK),新昌创展(01781.HK),WAC HOLDINGS(08619.HK)及信源企业(01748.HK)。

相关内容“公司业绩”汇友生命科学(08088.HK)首季亏损收窄至2077万元

该指数同时剔出汇友生命科学(08088.HK),ECARGO HOLDINGS,威华达控股(00622.HK),智傲控股(08282.HK),荣丰联合(03683.HK),MEGA EXPO HOLDINGS( 01360.HK),美瑞健康国际(02327.HK)及惠记集团(00610.HK)。

(Source: http://www.aastocks.com/sc/stocks/news/aafn-content/now.941090/popular-news)

28 Apr
2019

香港制药业初创企业與新加坡技术机构共同参与风险投资基金

<南华早报>
(新闻只有英文版本)

Aptorum Group, a Hong Kong drug developer listed on Nasdaq, will invest in health care start-ups in Singapore, working alongside the city state’s government technology agency to channel US$90 million into promising companies.

Aptorum and Aeneas Capital, both controlled by boutique investment bank co-founder Ian Huen Chung-yuen, signed an agreement with A*ccelerate Technologies on Wednesday to invest the funds over the next five years.

A*ccelerate operates under the Singapore’s Agency for Science, Technology and Research, and is tasked with helping to commercialise ideas and intellectual capital into marketable products and services.

The pact would allow Aptorum and Aeneas to leverage financial and technology development resources regionally and expand beyond Hong Kong when it comes to development of its own drug candidates.

“Hong Kong’s relatively small population means the number of patients for clinical trials is quite limited and trials need to be conducted elsewhere,” said Huen, Aptorum’s founder and chief executive. “Our collaboration with [the agency] ... will allow us to access and develop the excellent expertise and technological ecosystems in Singapore.”

Huen declined to divulge each party’s capital contribution toward the US$90 million, which will be deployed to support up to 20 start-ups.

Aptorum and the agency plan to cooperate in the application of solutions to enable more accurate 2D and 3D magnetic resonance imaging in the field of surgical robotics.

Aptorum, set up in 2017 through licensing agreements with units of the University of Hong Kong, Chinese University of Hong Kong and Hong Kong Polytechnic University, has obtained rights to further develop and commercialise various drugs.

These include drug candidates for influenza, MRSA – an antibiotics-resistant bacteria infection – and endometriosis, a painful disorder affecting women.

Huen said it expects to begin phase one clinical trials on three drug candidates between next year and 2021, each trial costing around US$5 million.

Having raised only US$12 million from its listing on Nasdaq in December, Huen said the company will need to raise additional funds over time.

The company employs around 80 staff, mainly in Hong Kong and operates a research facility at Science Park in Pak Shek Kok in the New Territories.

This article appeared in the South China Morning Post print edition as: HK drug firm looks to Singapore deals

(Sources: https://www.scmp.com/business/money/markets-investing/article/3007884/hong-kong-pharma-start-joins-singapore-technology)

26 Apr
2019

知临集团成立子公司Smart Pharma 专注计算机辅助药物再利用

<金融界>

  2019年4月24日/亚洲-新加坡,知临集团(纳斯达克股票代码:APM)今日宣布成立子公司Smart Pharma(“SmartP”)。SmartP主要运营创新的计算机辅助药物再利用之发现、建模和验证平台,相关平台统称为“Smart-ACTTM”平台。

  Smart-ACTTM代表了治疗药物加速商业化,并在系统地从现有已获批准的药物分子中筛选可针对特定治疗靶标的候选药物方面拥有顶尖技术。具体而言,Smart-ACTTM平台由一系列模块和流程组成,相关的模块和流程可模拟药物分子对疾病的有效性以实现结果预测和选择。Smart-ACTTM平台初期将专注于筛查孤儿病或未被满足的医疗需求之疾病的药物分子。

  截至目前,SmartP通过Smart-ACTTM平台已成功地完成对1,615种化合物靶向神经母细胞瘤(“NB”)预后不良相关的3种治疗靶点蛋白的筛查。NB是一种在某些类型的神经组织中形成的癌症,常见于肾上腺、脊柱、胸部、腹部以及颈部。Smart-ACTTM平台的初步研究结果已锁定了许多潜在的可再利用的候选药物,这些候选药物可能为治疗该种疾病带来希望。随后,SmartP将通过与知临集团的合作,进一步对该类候选药物进行体外和体内实验,以评估和验证候选药物对于该新适应症的可用性。

  药物再利用通常是将已获批准或正在开发的药物用于与其最初开发目标不同的适应症。这些药物分子的安全性和CMC特性通常是比较明确的,因此药物再利用意味着一种低风险的药物发现/开发方法。沙利度胺是众所周知的一个药物再利用成功案例,它最初用于治疗孕吐,但由于其存在出生缺陷的副作用而被迫退出市场。其后通过药物再利用开发,沙利度胺重新被用于治疗多发性骨髓瘤。

  通过Smart-ACTTM平台,SmartP的目标是每年发现高达10个再利用候选药物,该平台还将继续开发及丰富其知识产权库以促进此类发现。

  有关Smart-ACTTM平台的更多信息,请浏览我们的网站:http://www.smtph.com。

  知临集团与Smart Pharma的创始人禤骏远先生表示:“我们的Smart-ACTTM平台是一种创新的工具,它完全改变了传统上依赖于分散和偶然发现的药物再利用和发现行业。相反,我们Smart-ACTTM平台是基于计算机程序对药物分子进行系统性的筛查和预测,以加速治疗药物商业化进程。该平台初期专注研究孤儿疾病和未被满足医疗需求的疾病。知临集团对Smart Pharma取得的进展感到非常鼓舞,Smart Pharma将积极寻求与更广泛的行业进行合作和共同开发的机会。”

  关于知临集团

  知临集团是一家致力于开发和商业化多种治疗和诊断技术以解决未被满足之医疗需求的制药公司。当前,知临集团正在进行神经内科、传染病、胃肠病、癌症和其他疾病领域的治疗和诊断项目,以及非治疗领域如外科机器人(16.75 +0.78%,诊股)项目,并于香港运营医疗诊所——知仁医疗,该诊所初期着重于治疗现代久坐不动生活方式与人口老龄化所致的慢性病。

  有关知临集团的更多信息,请浏览www.aptorumgroup.com。

  关于Smart Pharma

  Smart Pharma的控股公司SMTPH有限公司及其集团公司均为知临集团全资子公司,专注于开发其Smart-ACTTM平台,以革新药物的发现和开发。

  有关Smart Pharma的更多信息,请浏览www.smpth.com.

  免责声明与前瞻性陈述

  本新闻稿包含有关知临集团及其未来预期、计划和前景的陈述,这些陈述构成了1995年“私人证券诉讼改革法案”界定的“前瞻性陈述”。为此目的,此处包含的任何非陈述历史事实的陈述均可被视为前瞻性陈述。在某些情况下,您可以通过诸如“可以”、“应该”、“预期”、“计划”、“预计”、“可能”、“打算”、“目标”、“项目”、“考虑”、“相信”、“估计”、“预测”、“潜在”或“继续”,或者这些术语及其他类似表达的否定形式来识别前瞻性陈述。知临集团的这些前瞻性陈述主要基于其目前的预期及其对认为可能影响其业务、财务状况和经营业绩的未来事件和趋势的预测。这些前瞻性陈述仅反映截止在本新闻稿发布之日的信息,并受若干风险、不确定性和假设的影响,包括但不限于与其宣布的管理和组织变更相关的风险、关键人员的持续服务和可用性、其通过为其他消费者细分市场提供额外产品而扩充产品线的能力、公司预期的增长战略、业务中的预期趋势和挑战、其对供应链的期望及供应链的稳定性,以及知临集团于2018年12月4日向美国证券交易委员会(“SEC”)提交的招股说明书(文件号333-227198)及未来知临集团可能向SEC提交的其他文件中更加充分描述的风险。知临集团不承担因新信息、未来事件或其他原因而更新本新闻稿中包含的任何前瞻性陈述的义务。

(Source: http://stock.jrj.com.cn/hotstock/2019/04/25093127479607.shtml)

×
×
×
×
使用条款

This Website contains information concerning Aptorum Group Limited (“Aptorum Group”) and its affiliates that may be useful to Aptorum Group’s customers, suppliers, employees, directors and shareholders, as well as members of the general public. However, by using this Website you are accepting all of the terms of this disclaimer notice, including exclusions and limitations of liability. If you do not agree with anything in this notice, you should not use this Website.

Aptorum Group does not claim ownership of the materials and product images on the Website that are provided to us by our third party suppliers.

Where our Website contains links to other sites and resources provided by third parties, these links are provided for your information only. We have no control over the contents of those sites or resources, and accept no responsibility for them or for any loss or damage that may arise from your use of them. These links are provided solely as a convenience to you and not as an endorsement by us of the contents on such third party websites.

While reasonable efforts are made to ensure that the contents of this Website are accurate, this Website and its contents are provided on an “as is,” “as available” basis, without warranties of any kind, including any warranty that the Website will be kept up to date, be true and not misleading, or that the Website will always (or ever) be available for use. Aptorum Group and its affiliates disclaim all warranties, express or implied, with respect to the Website and its contents, including, without limitation, any warranties of accuracy, completeness, timeliness, non-infringement, title, merchantability, or fitness for a particular purpose. Because some jurisdictions do not permit the exclusion of certain warranties, these exclusions may not apply to you.

In no event will Aptorum Group or its affiliates be liable for any incidental, indirect, consequential, or special damages of any kind, or any damages whatsoever, including, without limitation, those resulting from loss of profits, contracts, goodwill, data, information, income, anticipated savings, or business relationships, whether or not Aptorum Group or its affiliates have been advised of the possibility of such damage, arising out of or in connection with the use of this Website or its contents or any other sites linked to this Website.

If you have any concerns about material which appears on our Website, please contact us. We have the right and the ability to remove immediately from our Website any material that is infringing, defamatory, offensive, abusive, harming, deceptive, threatening or otherwise illegal.